AU2013359767B2 - Solution formulations of engineered anti-IL-23p19 antibodies - Google Patents

Solution formulations of engineered anti-IL-23p19 antibodies Download PDF

Info

Publication number
AU2013359767B2
AU2013359767B2 AU2013359767A AU2013359767A AU2013359767B2 AU 2013359767 B2 AU2013359767 B2 AU 2013359767B2 AU 2013359767 A AU2013359767 A AU 2013359767A AU 2013359767 A AU2013359767 A AU 2013359767A AU 2013359767 B2 AU2013359767 B2 AU 2013359767B2
Authority
AU
Australia
Prior art keywords
lot
pct
antibody
months
time
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013359767A
Other languages
English (en)
Other versions
AU2013359767A1 (en
Inventor
Aniket Badkar
Ramesh S. Kashi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Merck Sharp and Dohme LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50934859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2013359767(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Merck Sharp and Dohme LLC filed Critical Merck Sharp and Dohme LLC
Publication of AU2013359767A1 publication Critical patent/AU2013359767A1/en
Application granted granted Critical
Publication of AU2013359767B2 publication Critical patent/AU2013359767B2/en
Assigned to MERCK SHARP & DOHME LLC reassignment MERCK SHARP & DOHME LLC Request to Amend Deed and Register Assignors: MERCK SHARP & DOHME CORP.
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU2013359767A 2012-12-13 2013-12-09 Solution formulations of engineered anti-IL-23p19 antibodies Active AU2013359767B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261737035P 2012-12-13 2012-12-13
US61/737,035 2012-12-13
PCT/US2013/073825 WO2014093203A1 (en) 2012-12-13 2013-12-09 SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES

Publications (2)

Publication Number Publication Date
AU2013359767A1 AU2013359767A1 (en) 2015-07-23
AU2013359767B2 true AU2013359767B2 (en) 2018-04-05

Family

ID=50934859

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013359767A Active AU2013359767B2 (en) 2012-12-13 2013-12-09 Solution formulations of engineered anti-IL-23p19 antibodies

Country Status (31)

Country Link
US (2) US20210188964A1 (cg-RX-API-DMAC7.html)
EP (1) EP2931313B1 (cg-RX-API-DMAC7.html)
JP (1) JP6266012B2 (cg-RX-API-DMAC7.html)
KR (1) KR102004585B1 (cg-RX-API-DMAC7.html)
CN (1) CN104870016B (cg-RX-API-DMAC7.html)
AU (1) AU2013359767B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015013540B1 (cg-RX-API-DMAC7.html)
CA (1) CA2894869C (cg-RX-API-DMAC7.html)
CL (1) CL2015001608A1 (cg-RX-API-DMAC7.html)
CY (1) CY1121895T1 (cg-RX-API-DMAC7.html)
DK (1) DK2931313T3 (cg-RX-API-DMAC7.html)
EA (1) EA034616B1 (cg-RX-API-DMAC7.html)
ES (1) ES2732861T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20191137T1 (cg-RX-API-DMAC7.html)
HU (1) HUE045668T2 (cg-RX-API-DMAC7.html)
IL (3) IL278295B2 (cg-RX-API-DMAC7.html)
LT (1) LT2931313T (cg-RX-API-DMAC7.html)
MX (1) MX357936B (cg-RX-API-DMAC7.html)
MY (1) MY187921A (cg-RX-API-DMAC7.html)
NZ (1) NZ708443A (cg-RX-API-DMAC7.html)
PE (1) PE20151524A1 (cg-RX-API-DMAC7.html)
PH (1) PH12015501296A1 (cg-RX-API-DMAC7.html)
PL (1) PL2931313T3 (cg-RX-API-DMAC7.html)
PT (1) PT2931313T (cg-RX-API-DMAC7.html)
RS (1) RS59057B1 (cg-RX-API-DMAC7.html)
SI (1) SI2931313T1 (cg-RX-API-DMAC7.html)
SM (1) SMT201900414T1 (cg-RX-API-DMAC7.html)
TR (1) TR201909584T4 (cg-RX-API-DMAC7.html)
UA (1) UA117466C2 (cg-RX-API-DMAC7.html)
WO (1) WO2014093203A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201504408B (cg-RX-API-DMAC7.html)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI806150B (zh) 2014-11-07 2023-06-21 瑞士商諾華公司 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
JP7179717B2 (ja) * 2017-03-31 2022-11-29 Ｍｅｉｊｉ Ｓｅｉｋａファルマ株式会社 水性製剤及び注射器入り水性製剤、並びに、抗体タンパク脱凝集剤及び抗体タンパク脱凝集方法
MX2020009265A (es) * 2018-03-05 2020-10-01 Janssen Biotech Inc Metodos para tratar la enfermedad de crohn con un anticuerpo especifico anti-il23.
SG11202104166QA (en) * 2018-11-21 2021-05-28 Regeneron Pharma High concentration protein formulation
CN112334483B (zh) 2018-11-27 2022-05-10 信达生物制药(苏州)有限公司 抗IL-23p19抗体及其用途
US12493019B2 (en) 2019-02-20 2025-12-09 Amgen Inc. Methods of determining protein stability
AU2020279987A1 (en) 2019-05-23 2021-11-18 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to IL-23 and TNF alpha
US20210070852A1 (en) * 2019-09-09 2021-03-11 Boehringer Ingelheim International Gmbh Anti-IL-23p19 Antibody Formulations
US11396541B2 (en) 2019-12-20 2022-07-26 Novarock Biotherapeutics, Ltd. Anti-interleukin-23 P19 antibodies and methods of use thereof
BR112022022919A2 (pt) * 2020-05-13 2022-12-20 Innovent Biologics Suzhou Co Ltd Formulação compreendendo o anticorpo anti-il-23p19, método para preparar o mesmo e uso do mesmo".
CA3183927A1 (en) 2020-05-21 2021-11-25 Janssen Biotech, Inc. Method of treating inflammatory bowel disease with a combination therapy of antibodies to il-23 and tnf alpha
WO2025071362A1 (ko) * 2023-09-27 2025-04-03 삼성바이오에피스 주식회사 항-il-23 항체의 안정한 액상 제형

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229490A1 (en) * 2008-08-27 2011-09-22 Schering Corporation Lyophilized Formulations of Engineered Anti-IL-23p19 Antibodies

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2366706A1 (en) 1999-03-11 2000-09-14 Schering Corporation Mammalian cytokines; related reagents and methods
JP4505166B2 (ja) 1999-09-09 2010-07-21 シェーリング コーポレイション 哺乳動物インターロイキン−１２ｐ４０およびインターロイキンｂ３０、その組成物、抗体、薬学的組成物における使用
DE60235013D1 (de) 2001-07-25 2010-02-25 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
CA2466034C (en) * 2001-11-08 2012-12-18 Protein Design Labs, Inc. Stable aqueous pharmaceutical formulations of daclizumab antibodies
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
WO2004071517A2 (en) 2003-02-06 2004-08-26 Schering Corporation Uses of il-23 related reagents
DK2236154T3 (en) 2003-02-10 2018-06-25 Biogen Ma Inc IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT
EP1601694B1 (en) 2003-03-10 2009-08-26 Schering Corporation Uses of il-23 antagonists; related reagents
BRPI0403964B8 (pt) * 2003-04-04 2021-05-25 Genentech Inc formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
WO2005079837A1 (en) 2004-02-17 2005-09-01 Schering Corporation Methods of modulating il-23 activity; related reagents
WO2005117967A2 (en) 2004-04-12 2005-12-15 Medimmune, Inc. Anti-il-9 antibody formulations and uses thereof
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
HRP20130400T1 (en) 2005-06-30 2013-06-30 Janssen Biotech, Inc. Anti-il-23 antibodies, compositions, methods and uses
SI1937721T1 (sl) 2005-08-25 2010-11-30 Lilly Co Eli Anti il protitelesa
DK1931710T3 (en) 2005-08-31 2017-04-03 Merck Sharp & Dohme CONSTRUCTED ANTI-IL-23 ANTIBODIES
DK2548577T3 (en) 2005-12-29 2017-03-13 Janssen Biotech Inc HUMAN ANTI-IL-23 ANTIBODIES, COMPOSITIONS, PROCEDURES AND APPLICATIONS
CA2655372A1 (en) 2006-06-13 2007-12-21 Zymogenetics, Inc. Il-17 and il-23 antagonists and methods of using the same
MX2009003982A (es) 2006-10-20 2009-04-27 Amgen Inc Formulaciones de polipeptido estables.
AU2008204901A1 (en) 2007-01-09 2008-07-17 Wyeth Anti-IL-13 antibody formulations and uses thereof
TWI426918B (zh) 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
SG178804A1 (en) 2007-02-23 2012-03-29 Schering Corp Engineered anti-il-23p19 antibodies
US8293883B2 (en) * 2007-02-23 2012-10-23 Schering Corporation Engineered anti-IL-23P19 antibodies
EP2068923A4 (en) * 2007-03-30 2010-11-24 Medimmune Llc ANTIBODIES HAVING REDUCED DEAMIDATION PROFILES
US20090208492A1 (en) * 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
WO2009114040A2 (en) 2007-09-28 2009-09-17 Centocor Ortho Biotech Inc. Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses
AR068723A1 (es) 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
ES2511844T3 (es) 2007-12-21 2014-10-23 F. Hoffmann-La Roche Ag Formulación de anticuerpo
SG191639A1 (en) * 2008-06-03 2013-07-31 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2331090B1 (en) * 2008-09-19 2018-01-03 Pfizer Inc. Stable liquid antibody formulation
WO2010062896A1 (en) * 2008-11-28 2010-06-03 Abbott Laboratories Stable antibody compositions and methods for stabilizing same
KR20120110175A (ko) * 2009-12-29 2012-10-09 에프. 호프만-라 로슈 아게 항체 제제
DK2691112T3 (en) 2011-03-31 2018-07-30 Merck Sharp & Dohme STABLE FORMULATIONS OF ANTIBODIES AGAINST HUMAN PD (PROGRAMMED DEATH) 1- RECEPTOR AND RELATED TREATMENTS

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110229490A1 (en) * 2008-08-27 2011-09-22 Schering Corporation Lyophilized Formulations of Engineered Anti-IL-23p19 Antibodies

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WARNE N.W., "Development of high concentration protein biopharmaceuticals: The use of platform approaches in formulation development", EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2011, vol. 78, no. 2, pages 208 - 212 *

Also Published As

Publication number Publication date
KR20150092763A (ko) 2015-08-13
IL307581A (en) 2023-12-01
RS59057B1 (sr) 2019-08-30
IL278295A (cg-RX-API-DMAC7.html) 2020-12-31
BR112015013540B1 (pt) 2021-04-27
MX357936B (es) 2018-07-31
PT2931313T (pt) 2019-07-10
US20150329632A1 (en) 2015-11-19
HUE045668T2 (hu) 2020-01-28
JP2016505572A (ja) 2016-02-25
KR102004585B1 (ko) 2019-07-26
DK2931313T3 (da) 2019-07-15
SMT201900414T1 (it) 2019-09-09
WO2014093203A1 (en) 2014-06-19
ZA201504408B (en) 2017-09-27
BR112015013540A8 (pt) 2018-04-17
IL278295B2 (en) 2024-03-01
EP2931313A1 (en) 2015-10-21
US20240239884A1 (en) 2024-07-18
MX2015007213A (es) 2016-08-03
ES2732861T3 (es) 2019-11-26
JP6266012B2 (ja) 2018-01-24
PL2931313T3 (pl) 2019-10-31
CY1121895T1 (el) 2020-10-14
IL239150A0 (en) 2015-07-30
UA117466C2 (uk) 2018-08-10
IL239150B (en) 2020-11-30
BR112015013540A2 (pt) 2017-11-14
EA034616B1 (ru) 2020-02-27
PH12015501296B1 (en) 2015-08-24
CA2894869C (en) 2021-06-15
TR201909584T4 (tr) 2019-07-22
LT2931313T (lt) 2019-09-25
CA2894869A1 (en) 2014-06-19
NZ708443A (en) 2018-05-25
IL278295B1 (en) 2023-11-01
CL2015001608A1 (es) 2015-10-30
CN104870016B (zh) 2018-05-08
HRP20191137T1 (hr) 2019-09-20
AU2013359767A1 (en) 2015-07-23
EP2931313A4 (en) 2016-08-03
EP2931313B1 (en) 2019-05-08
EA201591133A1 (ru) 2015-10-30
SI2931313T1 (sl) 2019-09-30
PH12015501296A1 (en) 2015-08-24
HK1215194A1 (en) 2016-08-19
PE20151524A1 (es) 2015-11-06
US20210188964A1 (en) 2021-06-24
MY187921A (en) 2021-10-28
CN104870016A (zh) 2015-08-26

Similar Documents

Publication Publication Date Title
US20240239884A1 (en) SOLUTION FORMULATIONS OF ENGINEERED ANTI-IL-23p19 ANTIBODIES
CA2734919C (en) Lyophilized formulations of engineered anti-il-23p19 antibodies
KR102749243B1 (ko) Il-17 항체의 제약 제품 및 안정한 액체 조성물
US20180008707A1 (en) Stable liquid formulation for monoclonal antibodies
CN105051064A (zh) 抗TNF-α抗原结合蛋白
TWI802882B (zh) 包含抗IL-23p19抗體的製劑、其製備方法和用途
CN113453719A (zh) 包含抗cd47抗体的制剂及其制备方法和用途
US12509509B2 (en) Solution formulations of engineered anti-IL-23p19 antibodies
HK1215194B (en) Solution formulations of engineered anti-il-23p19 antibodies
HK40059591A (en) Preparations containing anti-cd47 antibody, and preparation method and use therefor

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
HB Alteration of name in register

Owner name: MERCK SHARP & DOHME LLC

Free format text: FORMER NAME(S): MERCK SHARP & DOHME CORP.